The Technical AnalystExchange: STO Sector: Healthcare Industry: Biotechnology
Elicera Therapeutics AB Price, Forecast, Insider, Ratings, Fundamentals & Signals
8.67% SEK1.065
America/New_York / 17 mai 2024 @ 11:29
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 21.07 mill |
| EPS: | -0.830 |
| P/E: | -1.280 |
| Earnings Date: | May 16, 2024 |
| SharesOutstanding: | 19.78 mill |
| Avg Daily Volume: | 0.126 mill |
| RATING 2024-05-17 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.280 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -1.280 | industry: PE 491.84 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
SEK 0.950 - 1.190 ( +/- 11.21%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK1.065 (8.67% ) |
| Volume | 0.609 mill |
| Avg. Vol. | 0.126 mill |
| % of Avg. Vol | 483.84 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ELIC.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ELIC.ST
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.